ImmuCell Corporation (NASDAQ:ICCC) Short Interest Down 42.6% in May

ImmuCell Corporation (NASDAQ:ICCC) saw a large decrease in short interest in May. As of May 15th, there was short interest totaling 10,435 shares, a decrease of 42.6% from the April 30th total of 18,194 shares. Approximately 0.1% of the shares of the stock are sold short. Based on an average daily volume of 27,303 shares, the days-to-cover ratio is currently 0.4 days.

Analyst Ratings Changes

Separately, Weiss Ratings cut shares of ImmuCell from a “hold (c-)” rating to a “sell (d-)” rating in a research report on Monday, April 6th. One equities research analyst has rated the stock with a Sell rating, According to MarketBeat, ImmuCell has a consensus rating of “Sell”.

Hedge Funds Weigh In On ImmuCell

Several institutional investors and hedge funds have recently added to or reduced their stakes in ICCC. Geode Capital Management LLC boosted its stake in shares of ImmuCell by 4.2% in the 2nd quarter. Geode Capital Management LLC now owns 71,852 shares of the biotechnology company’s stock valued at $500,000 after purchasing an additional 2,907 shares during the last quarter. Steadtrust LLC bought a new position in ImmuCell during the third quarter worth $198,000. Mesirow Financial Investment Management Inc. increased its holdings in shares of ImmuCell by 199.6% during the fourth quarter. Mesirow Financial Investment Management Inc. now owns 36,481 shares of the biotechnology company’s stock valued at $224,000 after acquiring an additional 24,303 shares in the last quarter. Dimensional Fund Advisors LP lifted its stake in shares of ImmuCell by 3.2% in the first quarter. Dimensional Fund Advisors LP now owns 56,030 shares of the biotechnology company’s stock valued at $355,000 after buying an additional 1,749 shares in the last quarter. Finally, Militia Capital Management LLC bought a new position in shares of ImmuCell in the first quarter valued at $114,000. 13.47% of the stock is currently owned by institutional investors and hedge funds.

ImmuCell Price Performance

ICCC stock traded up $0.12 during trading on Tuesday, reaching $9.79. 39,904 shares of the company were exchanged, compared to its average volume of 23,078. The company has a 50-day moving average of $8.07 and a two-hundred day moving average of $6.76. The company has a market capitalization of $88.60 million, a price-to-earnings ratio of -163.14 and a beta of 0.55. ImmuCell has a twelve month low of $4.52 and a twelve month high of $10.75. The company has a debt-to-equity ratio of 0.24, a current ratio of 4.82 and a quick ratio of 2.60.

ImmuCell (NASDAQ:ICCC) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $0.21 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.05 by $0.16. The business had revenue of $10.36 million during the quarter, compared to analysts’ expectations of $5.40 million. ImmuCell had a negative net margin of 1.82% and a negative return on equity of 1.88%.

About ImmuCell

ImmuCell Corporation (NASDAQ: ICCC) is a biotechnology company that develops, manufactures, and markets immunological products and diagnostic assays designed to enhance animal health in dairy and beef cattle. Headquartered in Portland, Maine, the company focuses on supporting herd health management through its portfolio of passive immunology solutions and veterinary diagnostics.

The company’s flagship offering, CalfGuard natural colostrum supplement, is formulated to promote the passive transfer of antibodies in newborn calves and reduce the incidence of neonatal diseases.